Harvard Apparatus Regenerative Technology, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. The company is headquartered in Holliston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2013-10-14. The company uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma, or birth defects. The firm is targeting the conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy and birth defects. Its additional product candidates in its development pipeline are targeted at the reconstruction of the colon and uterus wound repair. Its product candidate includes Cellspan Esophageal Implant, and Cellspan Bronchial Implants. The company is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection.